Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.52, p.219-224, 2005 |
||
Title: Modulation of BCRP mediated atypical multidrug resistance phenotype by RNA interference | ||
Author: WT., LI ; GY., ZHOU ; XR., SONG ; WL., CHI ; RM., REN ; XW., WANG ; | ||
Abstract: Multidrug resistance (MDR) in human cancers is one of the major
causes of failure of chemotherapy. The emergence of
breast cancer resistance protein (BCRP), a member of the ABC
transporter family, has necessitated the development of
antagonists.
To overcome the BCRP-mediated atypical multidrug drug resistance,
two small interfering RNA constructs
(RNAi) targeting two different regions of BCRP mRNA were designed
to inhibit the atypical MDR expression by
transfecting them into MCF-7/MX100 cell lines. The multidrug
resistance index to mitoxantrone and the intensity of
mitoxantrone fluorescence of MCF-7/MX100 decreased after
transfected by pSUPER-BCRP-A and pSUPER-BCRP-B respectively;
the BCRP mRNA level and the BCRP protein level of MCF-7/MX100
decreased after treated with
pSUPER-BCRPs. The two constructed RNAi plasmids could reverse the
atypical mutidrug resistance mediated by BCRP,
but neither can reversed it completely, this may due to low
transfection efficiency and transient transfection.
|
||
Keywords: BCRP, RNA interference, atypical MDR, breast cancer | ||
Year: 2005, Volume: 52, Issue: | Page From: 219, Page To: 224 | |
|
download file |
|